IL296539A - Farnesoid x receptor agonists for the treatment of disease - Google Patents

Farnesoid x receptor agonists for the treatment of disease

Info

Publication number
IL296539A
IL296539A IL296539A IL29653922A IL296539A IL 296539 A IL296539 A IL 296539A IL 296539 A IL296539 A IL 296539A IL 29653922 A IL29653922 A IL 29653922A IL 296539 A IL296539 A IL 296539A
Authority
IL
Israel
Prior art keywords
compound
disease
pharmaceutically acceptable
acceptable salt
liver
Prior art date
Application number
IL296539A
Other languages
English (en)
Hebrew (he)
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of IL296539A publication Critical patent/IL296539A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL296539A 2020-03-18 2021-03-17 Farnesoid x receptor agonists for the treatment of disease IL296539A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062991292P 2020-03-18 2020-03-18
US202063069667P 2020-08-24 2020-08-24
US202163140735P 2021-01-22 2021-01-22
PCT/US2021/022786 WO2021188688A1 (en) 2020-03-18 2021-03-17 Farnesoid x receptor agonists for the treatment of disease

Publications (1)

Publication Number Publication Date
IL296539A true IL296539A (en) 2022-11-01

Family

ID=77771857

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296539A IL296539A (en) 2020-03-18 2021-03-17 Farnesoid x receptor agonists for the treatment of disease

Country Status (12)

Country Link
US (1) US20230131804A1 (enExample)
EP (1) EP4121048A4 (enExample)
JP (1) JP7851856B2 (enExample)
KR (1) KR20220154801A (enExample)
CN (4) CN120732855A (enExample)
AU (1) AU2021240001A1 (enExample)
BR (1) BR112022018651A2 (enExample)
CA (1) CA3172205A1 (enExample)
IL (1) IL296539A (enExample)
MX (1) MX2022011579A (enExample)
TW (1) TWI895384B (enExample)
WO (1) WO2021188688A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852748B1 (en) 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof
CN120227340A (zh) 2020-03-18 2025-07-01 伊莱利利公司 法尼醇x受体激动剂的制剂
JP7664278B2 (ja) * 2020-03-18 2025-04-17 オルガノボ，インク． ファルネソイドｘ受容体アゴニストの結晶質形態
CN117018000B (zh) * 2023-08-29 2025-01-28 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用
WO2026149323A1 (en) * 2025-01-07 2026-07-16 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists
CN120837611B (zh) * 2025-09-22 2025-12-16 吉林大学 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2016233579A1 (en) * 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2018236275B2 (en) * 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
DK3596053T3 (da) * 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
EP3852748B1 (en) * 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
CN120732854A (zh) 2025-10-03
EP4121048A4 (en) 2024-06-12
US20230131804A1 (en) 2023-04-27
EP4121048A1 (en) 2023-01-25
JP7851856B2 (ja) 2026-04-27
CA3172205A1 (en) 2021-09-23
JP2023518397A (ja) 2023-05-01
KR20220154801A (ko) 2022-11-22
BR112022018651A2 (pt) 2022-11-29
AU2021240001A1 (en) 2022-10-13
CN115666559A (zh) 2023-01-31
WO2021188688A1 (en) 2021-09-23
TWI895384B (zh) 2025-09-01
CN120732855A (zh) 2025-10-03
CN120732856A (zh) 2025-10-03
TW202143961A (zh) 2021-12-01
MX2022011579A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
US20220323414A1 (en) Farnesoid x receptor agonists for the treatment of disease
TWI895384B (zh) 用於治療疾病之法尼醇x受體促效劑
IL309558A (en) Fibrosis treatment
JP2017528431A (ja) 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
CA3018132C (en) Use of elafibranor in the treatment of a cholestatic disease
US20200155650A1 (en) Combination treatment of NAFLD and NASH
TW202114672A (zh) 使用fxr促效劑的肝臟疾病之組合治療
WO2021188690A1 (en) Farnesoid x receptor agonists for the treatment of disease
HK40131843A (en) Farnesoid x receptor agonists for the treatment of diseases
HK40131844A (en) Farnesoid x receptor agonists for the treatment of disease
Maroni et al. The pathophysiology of gut–liver connection
Maroni¹ et al. The pathophysiology of gut-liver
US20250332176A1 (en) Treatment for fibrosis and inhibition of fibrosis
IL316446A (en) Treatment of digestive system diseases
Sumida et al. An eBook on Diabetes
HK1237676A1 (en) Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
JP2019537607A (ja) 非アルコール性脂肪性肝疾患の患者における線維化の抑制
Lesley et al. Present and future challenges in Type 2 diabetes
Vashist et al. Santosh Kumar Rai*, Rakesh Kumar, Amit Panwar, Mohd Imran Khan, Srinivasa Reddy B, Bhavishya
Quchan Non-alcoholic fatty liver disease and steatohepatitis: state-of-the-art on effective therapeutics based on the gold standard method for diagnosis